The World Health Organization (WHO) has officially recommended the use of a new class of weight-loss drugs to treat obesity and diabetes globally. These drugs, known as GLP-1 agonists, include popular brands like Ozempic, Wegovy, and Mounjaro. WHO’s endorsement marks the first time these medications have been acknowledged as essential for treating obesity, which affects millions worldwide.
The growing popularity of GLP-1 drugs is due to their ability to significantly aid weight loss, with some users shedding substantial amounts of weight. However, despite their effectiveness, the high costs of these medications remain a major barrier. In the U.S., for example, these drugs can exceed $1,000 per month, making them unaffordable for many, particularly in low-income countries where obesity and related diseases are on the rise.
In response to these concerns, WHO is calling for the mass production of affordable generic versions of these drugs. The organization believes that generic competition will drive down prices, making life-saving treatments more accessible to people in developing countries. WHO has added two key drugs, semaglutide (found in Ozempic and Wegovy) and tirzepatide (in Mounjaro), to its essential medicines list.
Semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, has shown to have significant health benefits beyond weight loss, including improving heart health and reducing risks associated with diabetes. Recent studies have shown that GLP-1 drugs lower the risk of hospitalization and premature death in heart patients by more than 40%. This makes them crucial for combating the global obesity and diabetes crisis.
Despite these health benefits, the high prices remain a major challenge. Research shows that generic versions of semaglutide could be produced in India for as little as $4 per month, a stark contrast to the high retail prices in developed nations. WHO urges pharmaceutical companies, like Novo Nordisk and Eli Lilly, to prioritize global accessibility and affordability by enabling generic production once patents expire in countries such as Canada, China, and India.
The WHO’s recommendation comes at a time when obesity and diabetes rates continue to rise worldwide. With over 800 million people living with diabetes and one in eight people obese globally, the need for affordable treatment has never been more urgent. By pushing for generics, the WHO hopes to make a significant impact on the fight against these health issues, offering a brighter future for those in need of affordable medication.